KR102757425B1 - 염증 질환의 치료를 위한 신규 화합물 및 그의 약학 조성물 - Google Patents

염증 질환의 치료를 위한 신규 화합물 및 그의 약학 조성물 Download PDF

Info

Publication number
KR102757425B1
KR102757425B1 KR1020207014284A KR20207014284A KR102757425B1 KR 102757425 B1 KR102757425 B1 KR 102757425B1 KR 1020207014284 A KR1020207014284 A KR 1020207014284A KR 20207014284 A KR20207014284 A KR 20207014284A KR 102757425 B1 KR102757425 B1 KR 102757425B1
Authority
KR
South Korea
Prior art keywords
methyl
pyridin
imidazo
amino
carbonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207014284A
Other languages
English (en)
Korean (ko)
Other versions
KR20200074178A (ko
Inventor
스티븐 에미엘 반 데르 플라스
오스카 만모리티
세바스티엔 로렌 자비에르 마르티나
피에테르 이사벨 로저 클라스
주반니 페트루 디우니수 코티
데니스 마우리스 아누트
미리암 로페즈 라모스
르네 알렉산드레 갈리엔
데이비드 아만티니
레지날드 크리스토프 자비에르 브리스
Original Assignee
갈라파고스 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 갈라파고스 엔.브이. filed Critical 갈라파고스 엔.브이.
Publication of KR20200074178A publication Critical patent/KR20200074178A/ko
Application granted granted Critical
Publication of KR102757425B1 publication Critical patent/KR102757425B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020207014284A 2017-10-20 2018-10-11 염증 질환의 치료를 위한 신규 화합물 및 그의 약학 조성물 Active KR102757425B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1717260.2A GB201717260D0 (en) 2017-10-20 2017-10-20 Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
GB1717260.2 2017-10-20
PCT/EP2018/077677 WO2019076716A1 (en) 2017-10-20 2018-10-11 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS RELATED THERETO FOR THE TREATMENT OF INFLAMMATORY DISORDERS

Publications (2)

Publication Number Publication Date
KR20200074178A KR20200074178A (ko) 2020-06-24
KR102757425B1 true KR102757425B1 (ko) 2025-01-20

Family

ID=60481889

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207014284A Active KR102757425B1 (ko) 2017-10-20 2018-10-11 염증 질환의 치료를 위한 신규 화합물 및 그의 약학 조성물

Country Status (30)

Country Link
US (2) US11564923B2 (https=)
EP (2) EP3697784B9 (https=)
JP (2) JP7292271B2 (https=)
KR (1) KR102757425B1 (https=)
CN (2) CN111225916B (https=)
AR (1) AR113784A1 (https=)
AU (2) AU2018350592B2 (https=)
CA (1) CA3079449A1 (https=)
CO (1) CO2020005200A2 (https=)
DK (1) DK3697784T5 (https=)
ES (1) ES2967432T3 (https=)
FI (1) FI3697784T5 (https=)
GB (1) GB201717260D0 (https=)
HR (1) HRP20231315T1 (https=)
HU (1) HUE063998T2 (https=)
IL (2) IL302615B2 (https=)
LT (1) LT3697784T (https=)
MA (1) MA50391B1 (https=)
MX (1) MX2020003863A (https=)
MY (1) MY205443A (https=)
PH (1) PH12020550230A1 (https=)
PL (1) PL3697784T3 (https=)
PT (1) PT3697784T (https=)
RS (1) RS64800B1 (https=)
SG (1) SG11202003516TA (https=)
SI (1) SI3697784T1 (https=)
SM (1) SMT202300377T1 (https=)
TW (2) TWI866258B (https=)
WO (1) WO2019076716A1 (https=)
ZA (1) ZA202002166B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201717260D0 (en) * 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
AU2020284742B2 (en) * 2019-05-28 2026-03-05 Mankind Pharma Ltd. Novel compounds for inhibition of Janus Kinase 1
CA3208361A1 (en) 2021-02-19 2022-08-25 Anjali Pandey Tyk2 inhibitors and uses thereof
EP4294806A1 (en) 2021-02-19 2023-12-27 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
AU2022222470A1 (en) 2021-02-19 2023-09-21 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
AU2022310901A1 (en) 2021-07-12 2024-02-22 Galapagos Nv Treatment of inflammatory diseases
AU2022412835A1 (en) 2021-12-16 2024-06-20 Lynk Pharmaceuticals Co. Ltd. Tyk2 inhibitors and compositions and methods thereof
WO2023161326A1 (en) 2022-02-24 2023-08-31 Galapagos Nv Compound for use in and methods of treatment of inflammatory diseases
WO2023161327A1 (en) 2022-02-24 2023-08-31 Galapagos Nv Compound for use in and methods of treatment of inflammatory diseases
JP2024082106A (ja) * 2022-12-07 2024-06-19 富士通株式会社 情報処理プログラム、情報処理方法および情報処理装置
CR20250317A (es) 2023-01-18 2025-08-29 Galapagos Nv Composiciones farmacéuticas para el tratamiento de trastornos inflamatorios
AU2024209905A1 (en) 2023-01-19 2025-09-04 Galapagos Nv Imidazo[4,5-b]pyridine derivatives useful for the treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, autoimmune diseases and proliferative diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013116291A1 (en) 2012-01-30 2013-08-08 Cephalon, Inc. Imidazo [4, 5 - b] pyridine derivatives as alk and jak modulators for the treatment of proliferative disorders
WO2015110378A1 (en) 2014-01-23 2015-07-30 Galapagos Nv Benzimidazole derivatives and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102127078A (zh) * 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
WO2017012647A1 (en) 2015-07-20 2017-01-26 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AR105400A1 (es) * 2015-08-04 2017-09-27 Lilly Co Eli Inhibidores de jak1
EP3528816A4 (en) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
GB201717260D0 (en) * 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013116291A1 (en) 2012-01-30 2013-08-08 Cephalon, Inc. Imidazo [4, 5 - b] pyridine derivatives as alk and jak modulators for the treatment of proliferative disorders
WO2015110378A1 (en) 2014-01-23 2015-07-30 Galapagos Nv Benzimidazole derivatives and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
ES2967432T3 (es) 2024-04-30
BR112020007541A2 (pt) 2020-09-24
FI3697784T5 (fi) 2024-01-12
RS64800B1 (sr) 2023-11-30
SMT202300377T1 (it) 2024-01-10
CN111225916B (zh) 2023-11-03
IL302615B2 (en) 2024-10-01
AU2018350592A1 (en) 2020-06-04
EP3697784B9 (en) 2023-12-27
IL273943B1 (en) 2023-06-01
FI3697784T3 (fi) 2023-10-31
AU2023201522B2 (en) 2024-11-28
IL302615B1 (en) 2024-06-01
EP3697784A1 (en) 2020-08-26
TW201918483A (zh) 2019-05-16
SI3697784T1 (sl) 2023-11-30
EP3697784B1 (en) 2023-10-04
HUE063998T2 (hu) 2024-02-28
RU2020116376A (ru) 2021-11-22
EP4265254A2 (en) 2023-10-25
GB201717260D0 (en) 2017-12-06
JP2020537672A (ja) 2020-12-24
HRP20231315T1 (hr) 2024-02-16
CN117534670A (zh) 2024-02-09
CA3079449A1 (en) 2019-04-25
JP7654031B2 (ja) 2025-03-31
AR113784A1 (es) 2020-06-10
AU2018350592B2 (en) 2022-12-22
TWI805629B (zh) 2023-06-21
CO2020005200A2 (es) 2020-05-29
ZA202002166B (en) 2021-05-26
PT3697784T (pt) 2024-01-09
US20230310433A1 (en) 2023-10-05
IL273943A (en) 2020-05-31
PL3697784T3 (pl) 2024-03-11
LT3697784T (lt) 2023-10-25
WO2019076716A1 (en) 2019-04-25
JP7292271B2 (ja) 2023-06-16
TW202411229A (zh) 2024-03-16
CN111225916A (zh) 2020-06-02
US12472181B2 (en) 2025-11-18
TWI866258B (zh) 2024-12-11
US11564923B2 (en) 2023-01-31
SG11202003516TA (en) 2020-05-28
DK3697784T3 (da) 2023-10-30
RU2020116376A3 (https=) 2021-11-22
KR20200074178A (ko) 2020-06-24
IL302615A (en) 2023-07-01
DK3697784T5 (da) 2024-01-15
US20210169879A1 (en) 2021-06-10
MA50391A (fr) 2021-04-21
MY205443A (en) 2024-10-22
IL273943B2 (en) 2023-10-01
MX2020003863A (es) 2020-08-13
JP2023113834A (ja) 2023-08-16
PH12020550230A1 (en) 2021-02-08
AU2023201522A1 (en) 2023-04-13
EP4265254A3 (en) 2024-03-13
MA50391B1 (fr) 2023-11-30

Similar Documents

Publication Publication Date Title
KR102757425B1 (ko) 염증 질환의 치료를 위한 신규 화합물 및 그의 약학 조성물
KR102720958B1 (ko) 질병의 치료를 위한 신규 화합물 및 그의 약학 조성물
KR102758615B1 (ko) 질병의 치료를 위한 신규 화합물 및 그의 약학 조성물
US12606554B2 (en) Compounds and pharmaceutical compositions thereof for the treatment of diseases
WO2021032582A1 (en) Pyrazolo[4,3-c]pyridine derivatives and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2021032323A1 (en) Fused pyrimidine compounds and pharmaceutical compositions thereof for the treatment of fibrotic diseases
HK40101992A (en) Imidazo[4,5-b]pyridine compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
RU2785126C2 (ru) Новые соединения и их фармацевтические композиции для лечения воспалительных заболеваний
HK40035999A (en) Imidazo[4,5-b]pyridine compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
HK40035999B (en) Imidazo[4,5-b]pyridine compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
BR122025019954A2 (pt) Compostos, composições farmacêuticas e seus usos para o tratamento de distúrbios inflamatórios
BR112020007541B1 (pt) Compostos, composições farmacêuticas e seus usos para o tratamento de distúrbios inflamatórios

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200519

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211006

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231113

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241030

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250115

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250116

End annual number: 3

Start annual number: 1

PG1601 Publication of registration